Research identifies ENPP1 mutations as a driver of cisplatin resistance in hypopharyngeal squamous cell carcinoma, implicating the STING/NF-κB/IL-6 signaling axis. This discovery could inform future therapeutic strategies for overcoming treatment resistance.
from initial complete response to recurrence enpp1 mutation drives cisplatin resistance through sting nf b il 6 axis in hypopharyngeal squamous cell carcinoma
Original title: “From initial complete response to recurrence: ENPP1 mutation drives cisplatin resistance through STING/NF-κB/IL-6 axis in hypopharyngeal squamous cell carcinoma.”